In principle, many of these p53-imposed alterations on tumor cell EV secretion could be used clinically for diagnostic purposes, as prognostic biomarkers or, ideally, as novel targets for the treatment of the particularly therapeutically challenging class of p53-mutant cancers. The gene discussed is TP53; the disease is neoplasm.